Mesoblast (MESO) to Release Quarterly Earnings on Wednesday

Mesoblast (NASDAQ:MESO) is anticipated to issue its H2 2025 results before the market opens on Wednesday, August 27th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $7.4810 million for the quarter. Parties may review the information on the company’s upcoming H2 2025 earningreport for the latest details on the call scheduled for Wednesday, September 10, 2025 at 6:00 PM ET.

Mesoblast Stock Performance

MESO opened at $15.14 on Wednesday. The stock’s 50 day moving average price is $13.18 and its two-hundred day moving average price is $13.15. The company has a quick ratio of 0.63, a current ratio of 0.96 and a debt-to-equity ratio of 0.22. Mesoblast has a 12-month low of $6.00 and a 12-month high of $22.00.

Hedge Funds Weigh In On Mesoblast

A number of hedge funds have recently modified their holdings of MESO. Raymond James Financial Inc. acquired a new position in shares of Mesoblast in the 2nd quarter worth approximately $86,000. Creative Planning acquired a new position in shares of Mesoblast in the 2nd quarter worth approximately $141,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Mesoblast in the 1st quarter worth approximately $3,209,000. 1.43% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MESO has been the topic of a number of research analyst reports. Canaccord Genuity Group raised Mesoblast to a “strong-buy” rating in a report on Tuesday, August 5th. Jefferies Financial Group downgraded Mesoblast from a “buy” rating to a “hold” rating in a research report on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $18.00.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.